click to enlarge
From left ro right, UNC scientists Zylka, Roth and Philpot.
Media contact: Les Lang, (919) 966-9366, email@example.com
Thursday, Feb. 24, 2011
CHAPEL HILL, N.C. - Drs. Ben Philpot, Mark Zylka, and Bryan Roth have been awarded a $1,050,000 grant from the Simons Foundation to identify drug-like compounds for the treatment of autism spectrum disorders.
The three-year grant includes work with an animal model of Angelman syndrome, a neurodevelopmental disorder caused by inactivation of the Ube3a gene. Most cases of autism spectrum disorder are caused by defects in multiple genes, making the disorder particularly difficult to treat. In contrast, the loss of a single gene, UBE3A, causes a severe intellectual disability, Angelman syndrome, an autism spectrum disorder. Some forms of autism may also be caused by chromosomal duplications involving UBE3A.
Drs. Philpot, Zylka and Roth are affiliated with the Carolina Institute for Developmental Disabilities, UNC Neuroscience Center, the Department of Cell and Molecular Physiology (Philpot, Zylka) and the Department of Pharmacology (Roth).
Further details can be found at the Simons Foundation website.
Also see the lab websites for Drs. Philpot, Zylka and Roth.